Q4 EPS Estimate for CRISPR Therapeutics Raised by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Brookline Capital Management lifted their Q4 2025 EPS estimates for shares of CRISPR Therapeutics in a report released on Monday, November 10th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.81) for the quarter, up from their previous estimate of ($1.27). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ FY2028 earnings at $8.70 EPS and FY2029 earnings at $41.58 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.15. The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.49%.

Several other research firms have also recently issued reports on CRSP. Needham & Company LLC decreased their price target on CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a report on Monday. Royal Bank Of Canada lifted their price target on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Finally, Robert W. Baird dropped their target price on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $68.11.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $55.21 on Wednesday. The business’s fifty day moving average price is $63.03 and its two-hundred day moving average price is $53.45. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of -9.88 and a beta of 1.89. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $78.48.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares in the company, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 56,213 shares of company stock valued at $3,810,458 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. ARK Investment Management LLC increased its position in shares of CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after acquiring an additional 1,192,336 shares during the last quarter. IVC Wealth Advisors LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $225,000. Koss Olinger Consulting LLC increased its holdings in shares of CRISPR Therapeutics by 29.8% in the second quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock valued at $2,052,000 after purchasing an additional 9,685 shares during the last quarter. Vanguard Group Inc. grew its holdings in CRISPR Therapeutics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after buying an additional 33,711 shares in the last quarter. Finally, Slow Capital Inc. increased its position in CRISPR Therapeutics by 15.6% during the 2nd quarter. Slow Capital Inc. now owns 75,396 shares of the company’s stock worth $3,667,000 after buying an additional 10,152 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.